Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Autologous γδT cells in advanced HBV-related HCC
NCT04032392Phase 1Unknown
- Sponsor
- The Fifth Medical Center of the PLA General Hospital
- Start
- Jul 2019
- Primary completion
- Jul 2021
- Modality
- Adoptive Cell Transfer
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of autologous γδT cells in hepatocellular carcinoma (HCC), sponsored by The Fifth Medical Center of the PLA General Hospital. Primary endpoints: Incidence of adverse events and serious adverse events at 14 months and Overall Survival at 14 months. Status: unknown.
02
Drugs
autologous γδT cells
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on NCT04032392.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04032392.